key: cord-0879443-tmtbbnuz
authors: Napolitano, Valeria; Dabrowska, Agnieszka; Schorpp, Kenji; Mourão, André; Barreto-Duran, Emilia; Benedyk, Malgorzata; Botwina, Pawel; Brandner, Stefanie; Bostock, Mark; Chykunova, Yuliya; Czarna, Anna; Dubin, Grzegorz; Fröhlich, Tony; Hoelscher, Michael; Jedrysik, Malwina; Matsuda, Alex; Owczarek, Katarzyna; Pachota, Magdalena; Plettenburg, Oliver; Potempa, Jan; Rothenaigner, Ina; Schlauderer, Florian; Szczepanski, Artur; Mohn, Kristin Greve-Isdahl; Blomberg, Bjorn; Sattler, Michael; Hadian, Kamyar; Popowicz, Grzegorz Maria; Pyrc, Krzysztof
title: Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses
date: 2021-03-21
journal: bioRxiv
DOI: 10.1101/2021.03.20.436259
sha: 856d4877e1b483f73dc90189e1eade63e2d264d6
doc_id: 879443
cord_uid: tmtbbnuz

The COVID-19 pandemic caused by SARS-CoV-2 has been socially and economically devastating. Despite an unprecedented research effort, effective therapeutics are still missing to limit severe disease and mortality. Using high-throughput screening, we identified acriflavine as a potent papain-like protease (PLpro) inhibitor. NMR titrations and a co-crystal structure confirm that acriflavine blocks the PLpro catalytic pocket in an unexpected binding mode. We show that the drug inhibits viral replication at nanomolar concentration in cellular models, in vivo in mice and ex vivo in human airway epithelia, with broad range activity against SARS-CoV-2 and other betacoronaviruses. Considering that acriflavine is an inexpensive drug approved in some countries, it may be immediately tested in clinical trials and play an important role during the current pandemic and future outbreaks.

Coronaviruses have been considered a potential threat since 2002, when the severe, acute respiratory syndrome coronavirus (SARS-CoV) emerged in southern China spreading across continents but disappearing shortly thereafter (Drosten et al., 2003; Ksiazek et al., 2003) . Ten years later, Middle-East respiratory syndrome coronavirus (MERS-CoV) posed a pandemic 5 threat, but despite high fatality rates, the human-to-human transmission remained limited (Zaki et al., 2012) . Despite these warnings, the emergence of the SARS-CoV-2 and subsequent pandemic found healthcare largely unprepared and has paralyzed the modern world in an unprecedented way (Iacobucci, 2020; Ma et al., 2020; Mirzaei et al., 2020) .

First vaccines are available and applied already, and further approvals are expected shortly 10 (Parker et al., 2020) . However, the time needed for vaccination of the global population, limited availability of vaccines, reluctance to vaccinate, and reduced effectiveness of vaccination against newly emerging variants underline the urgent need for effective antivirals (Saha et al., 2020) . The timeline of preclinical to clinical development of novel antivirals, however, is too long for completely new compounds to make a clinical impact during the current pandemic. 15 Repurposing existing drugs with known safety profiles is, therefore, the most efficient and promising option. Initial candidates, unfortunately, did not fulfill expectations (Cao et al., 2020; Horby et al., 2020) . Some other leads are still being tested in the clinic, but no convincing proof of efficacy has been provided as yet (Pan et al., 2020; Simonovich et al., 2020) . Importantly, it has been proposed that the identification of a set of antivirals against SARS-CoV-2 may provide 20 an opportunity to mimic the strategy effective for HIV-1 -combinatorial treatment against different molecular targets (Lu et al., 2018) .

The coronaviral genome encodes several structural and non-structural proteins (Knipe and Howley, 2013) , including two cysteine proteases, M pro (nsp5) and PL pro (nsp3), essential for the virus replication (Shamsi et al., 2021) . While extensive actions to identify inhibitors of M pro 25 have been undertaken (Capasso et al., 2020) , only scarce information is available for the PL pro .

The latter protease is essential for viral protein maturation and has also been attributed to other functions, including type I interferon response attenuation, making it a viable therapeutic target (Shin et al., 2020) .

Here, we discovered acriflavine (ACF) as an effective inhibitor of SARS-CoV-2. 5 Acriflavine (ACF) is a mixture of trypaflavines (3,6-diamino-10-methylacridinium chloride and 3,6-diamino-3-methylacridinium chloride) and proflavine (3,6-diaminoacridine). ACF has been used systemically against sleeping sickness, urinary tract infections, and gonorrhea and has been suggested effective in a number of other indications (Dana et al., 2014; Funatsuki et al., 1997; Kawai and Yamagishi, 2009; Manchester et al., 2013; Mathé, 2000; Pépin et al., 2017; 10 Persinoti et al., 2014; Tripathi et al., 2006) . ACF was tested in a clinical trial against HIV where up to 100 mg daily was administered over the course of several months. Despite the chemical structure suggesting possible DNA intercalation and liver toxicity, no adverse effects were observed in these studies (Mathé et al., 1996; Mathé et al., 1998) . ACF has been approved in the past and was present in European pharmacopeias for systemic use (Browning, 1943 (Browning, , 1967 15 Mathé et al., 1998; Wainwright, 2001) . In some countries, ACF is currently available as an over-the-counter medicine (e.g., Brazil -EMS Cystex) against urinary tract infections. Its safety and efficacy were tested in a recently reconfirmed in a clinical trial in Brazil (Gama CRB, 2020; NCT03379389, 2020) . In other countries, ACF is used as a content of mouthwash advised for children ("Michino" gargle in Japan) (Lee et al., 2009) . The extensive available studies on 20 the long-term systemic administration of large doses of ACF have not revealed any major side effects, suggesting that it could be employed alone or in combination with other drugs (Nehme et al., 2020) .

Our data demonstrate that ACF is a potent inhibitor of SARS-CoV-2 PL pro, opening a promising therapeutic approach against COVID-19. The mode of action is confirmed by 25 structural characterization with X-ray crystallography and NMR, demonstrating that ACF specifically inhibits the active site of the enzyme with an unprecedented binding mode. We show that ACF blocks the virus infection in vitro. Importantly, the viral infection is also suppressed ex vivo in human airway epithelium (HAE) cultures, which recapitulate the fullydifferentiated human airway epithelium, as well as in an in vivo mouse model. Finally, we 5 provide evidence for ACF's antiviral effect against other betacoronaviruses, making this a potentially important therapeutic against future pandemics.

ACF was identified in a high-throughput screening approach for inhibitors of PL pro . We established a protease assay using a fluorogenic substrate. The overall scheme of this study is presented in Figure 1A . Based on the screening of a library consisting of 5,632 small molecule compounds, which are either approved or are/have been at various stages of clinical testing (Corsello et al., 2017) Figure S1 ). Acriflavine (ACF) was the most active compound with a dose-dependent PL pro inhibition with an IC50 of 1.66 µM ( Figure 1B ). Next, we tested the effect of ACF on PL pro enzymatic activity using the ISG15-AMC probe as substrate (Klemm et al., 2020; Shin et al., 2020) . As shown previously, PL pro cleaves ISG15-AMC significantly faster compared to RLRGG-AMC. Nonetheless, the IC50 of ACF with ISG15-AMC (1.46 µM) 20 ( Figure 1B, Supplementary Figure S2B ;) was comparable to the IC50 determined with the RLRGG-AMC substrate. To eliminate possible fluorescence artifacts, we conducted gel-based de-ubiquitination assays to confirm our results. We incubated K48 tri-ubiquitin with PL pro and took samples at different time points to analyze the cleavage by Western Blot. PL pro efficiently cleaved K48 tri-ubiquitin to di-ubiquitin ( Figure 1C ) as previously shown (Klemm et al., 2020) . 25 Next, PL pro was incubated with either DMSO or 5, 15, 25 µM of ACF before adding K48 triubiquitin chains to the reaction mixture. Also, in this independent assay format, ACF reduced the protease activity in a dose-dependent manner (Figure 1C) , thereby confirming that ACF is a specific PL pro inhibitor.

To evaluate the specificity of ACF we performed an enzymatic digestion assay using 5 fluorescent M pro substrate. This experiment shows that ACF is a very weak M pro inhibitor with less than 50% inhibition at 100 µM of ACF concentration (Supplementary Figure S3) .

Therefore, we conclude that M pro inhibition by acriflavine is not a significant force in reducing SARS-CoV-2 replication.

In order to confirm that ACF binds directly to PL pro in solution we recorded 2D 1 H, 15 N TROSY NMR spectra of recombinant 15 N-labeled PL pro in the absence and presence of ACF.

The spectra of PL pro are consistent with a globular folded, monomeric protein in solution ( Figure 2A ). The addition of ACF induces chemical shift changes for a number of amide signals 15 while not affecting the remaining bulk of the resonances. This confirms that the overall fold and monomeric state of the protein are not affected and demonstrates that ACF binds to a spatially localized site in PL pro .

To understand the molecular basis of the SARS-CoV2-PL pro inhibition by acriflavine, we determined the X-ray crystal structure of the protease in complex with proflavine, one of the 20 principal components of ACF. Analysis of the electron density map shows that two molecules of proflavine are π-π stacked to each other and accommodate the S3-S5 pockets of the PL pro substrate recognition cleft, which is defined by the loop connecting the helices 3 and 4 and the so-called "blocking loop" BL2 ( Figure 2B ) (Ratia et al., 2006) . Comparison with the apo structure of PL pro (PDB code: 7D47) revealed that, although the overall structure is well 25 preserved, the BL2 loop undergoes a large conformational change upon binding of the ligand.

In particular, the side chain of Tyr268 rotates by around 57° inwards towards the substrate recognition cleft, and the BL2 loop moves by 2 Å in the same direction, narrowing the substratebinding cleft (Supplementary Figure S4) .

Several PL pro residues are involved in ligand binding. One of the molecules termed 5 proflavine-I occupies the S4 pocket ( Figure 2B , C, D). The side chain Tyr273 is involved in a hydrogen bond (2.9 Å) with the primary amine group at position 3 of proflavine I, which sits at the bottom of the substrate-binding cleft, where it forms a T-stacked CH/π interaction with Pro247 (3.9 Å). A parallel stacking CH/π interaction with Pro248 (4.6 Å) and T-shaped π-π stacking with the aromatic side chain of Tyr264 is engaged in a T-shaped π-π stacking 10 interaction (3.5 Å) further stabilize the interaction with proflavine I. The second molecule, termed proflavine-II, shows π-π stacking at 3.5 Å with proflavine-I and occupies the S3 and S5 pockets ( Figure 2D , E). Gly163 and Asp164 form hydrogen bonds with the primary amine group at position 3 (2.9 Å) and the imino group of the acridine moiety (2.9 Å), respectively. In addition, Tyr268 forms a T-shaped π-π stacked interaction (5.1 Å) with proflavine-II. Overall, 15 this provides a unique binding mode, where two proflavines, tightly π-π stacked, cooperate in blocking the substrate pocket. Importantly, both molecules are required for the inhibition.

Recently, Shin et al. reported the crystal structure of SARS-CoV2-PL pro in complex with ISG15 (interferon-induced gene 15) bearing the RLRGG recognition motif at the C-terminus (Shin et al., 2020) . Comparison with our structure shows that the proflavine-II molecule, which 20 occupies the S3 and S5 pockets, overlaps very well with the backbone of Arg151 and Arg153 in the RLRGG peptide in positions P3 and P5, respectively (Figure 2E, F) . The side chain of Leu152 in position P4 points exactly towards the other molecule of proflavine in the S4 pocket.

All the major interactions of the substrate with PL pro residues are recapitulated by the inhibitor.

Mechanistically, these observations indicate that proflavine inhibits SARS-CoV2-PL pro by 25 limiting access to the substrate-binding site. Moreover, the fact that the imino group of the proflavine-I molecule in the S4 pocket is not involved in any polar interactions suggests that the methylated (acriflavine) form is preferred at this position due to lack of desolvation penalty.

The amino group at position 3 of proflavine-II is located in a similar position as the amide nitrogen of the RLRGG glycine P2 in the P2 pocket. Side-methylated proflavine, which is also 5 present in commercial acriflavine preparations (see Supplementary Analysis), would, therefore, mimic the P2 amino acid. These two expected interactions of commercial acriflavine explain why it is a significantly more potent inhibitor than pure proflavine. Intriguingly, a unique and important feature of the commercial acriflavine mixtures is that they contain the combination of methylated proflavines to optimally block the PL pro active site.

For cellular validation of ACF activity, two SARS-CoV-2 infection cell culture models were used: Vero cells, which are a broadly used simian model, and human A549 ACE2+ cells overexpressing the ACE2 receptor (Milewska et al., 2020) . First, the cytotoxicity of ACF was 15 evaluated on cell lines (A549 ACE2+ , Vero, HCT-8, CRFK) as well as primary human fibroblasts ( Figure 3A, Supplementary Figure S5 ). The cellular cytotoxicity CC50 values were determined in both cell types to be 3.1 µM for A549 ACE2+ , 3.4 µM for Vero, 2.1 µM for HCT-8, and 12 µM for primary human fibroblasts. Interestingly, ACF shows lower cytotoxicity in primary cells compared to transformed cell lines, which may reflect the previously described 20 antineoplastic activity of ACF (Lee et al., 2014) . Secondly, dose-response experiments were carried out in A549 ACE2+ and Vero cells (Figure 3B) . The IC50 values determined for ACF are 86 nM and 64 nM for A549 ACE2+ cells and Vero cells, respectively. Accordingly, the selectivity index (SI) values for A549 ACE2+ and Vero cells are 36 and 53, thus representing a potent inhibitor of SARS-CoV-2 virus replication with a favorable cytotoxicity profile. Notably, ACF 25 inhibition at 400 nM is significantly more effective than inhibition by remdesivir at 25-fold higher concentration in these assays ( Figure 3B ).

were first infected with the virus, and the ACF was added after 0, 2, 4, or 6 h. The results show that virus inhibition was maintained, even when the compound was not present during the early 5 stages of infection. Consequently, we conclude that SARS-CoV-2 is mainly inhibited during the replication phase, and ACF does not affect viral entry (Figure 3C ).

Inhibition of virus replication by ACF was further confirmed using confocal microscopy.

24 h and 48 h post-infection in the presence or absence of 500 nM ACF or 10 M remdesivir, confocal microscopy images showed nearly complete elimination of SARS-CoV-2 when 10 compared to untreated cells. While virus elimination is also observed for remdesivir, this is only seen at more than 20-fold higher concentrations compared to ACF (Figure 4A ).

The antiviral activity of ACF was analyzed in the HAE ex vivo model. Two different hours to control levels, 500 nM ACF treatment kept the virus at low titers.

After 6 days of infection in the presence of 500 nM ACF, confocal microscopy images showed complete inhibition of SARS-CoV-2 replication. While inhibition was also noted for remdesivir. However, the virus particles in remdesivir treated cells were still present on the cell surface, suggesting that a detectable level of virions was still produced. Therefore, the inhibition by 10 µM remdesivir was inferior compared to 500 nM ACF (Figure 4C) . 5 

To verify whether ACF may be used as a broadband anticoronaviral drug, its activity was tested against betacoronaviruses other than SARS-CoV-2, i.e., MERS-CoV and HCoV-OC43, as well as alphacoronaviruses, i.e., HCoV-NL63 and feline infectious peritonitis virus (FIPV).

ACF efficiently inhibited MERS-CoV (IC50 = 21 nM, SI = 162) and HCoV-OC43 (IC50 = 105 nM, SI = 27). Interestingly, no effect on the replication of tested alphacoronaviruses was observed ( Figure 5) . These data reveal that ACF can be used to inhibit betacoronaviruses in a broader sense and could represent a drug for future outbreaks.

To confirm that ACF can block virus replication in vivo we used an infection model based on K18-ACE2 mice. The experiment groups consisted of infection control receiving no treatment, ACF administered orally (p.o.; 100 mg/kg daily), two groups receiving ACF intramuscularly (i.m.; 5 mg/kg or 15 mg/kg body weight twice a day), and a positive control group receiving 20 remdesivir (i.m.; 25 mg/kg per day). We chose a high dose of oral administration to alleviate low bioavailability and relatively fast elimination of the drug. The administration of the ACF and remdesivir started one day prior to infection with SARS-CoV-2 virus. The treatment was continued for six consecutive days.

In all groups, the animals survived the infection until the last day, and no apparent signs of the disease were noted, including lack of change in the body weight. There were also no drugrelated adverse effects. Analysis of the virus replication levels by RT-qPCR on day 6 in the untreated group clearly shows that the virus replicated in lungs and brains. Treatment with acriflavine (both p.o. and i.m.) almost completely blocked the infection in the brain ( Figure   5 6A), while the positive control remdesivir only decreased the viral loads by 2-3 orders of magnitude. The infection levels were less pronounced in the lungs, but suppressed replication of the virus was also recorded for treatment groups, with the most pronounced effect (1-2 orders of magnitude reduction) observed for the p.o. administration of ACF ( Figure 6B ).

SARS CoV-2 is the cause of the most devastating global pandemic since the 1918 influenza. Despite the large commitment, early efforts failed to deliver effective antivirals to control the infection. Drugs inhibiting virus replication should be given early during the infection, but the required early diagnosis and the availability and costs involved render this 5 challenging. A cheap, easily accessible drug-like ACF might offer the required early availability and accessibility. Moreover, compounds of limited efficacy in monotherapy may serve as part of a combination therapy strategy (Lu et al., 2018) , as the synergy between the compounds targeting different molecular targets may be favorable.

Here, we focused on one of the viral proteases, PL pro , which is indispensable for SARS-10 CoV-2 replication, progeny production, and attenuation of the host's immune responses (Knipe and Howley, 2013; Shin et al., 2020) . PL pro modulates the ISGylation pathway, which acts as a viral defense mechanism to inhibit normal protein translation. ISGylation modifies protein kinase R, so that newly synthesized (viral) proteins are tagged as dangerous (Villarroya-Beltri et al., 2017) . Inhibition of PL pro will not only interfere with virus protein maturation, but 15 additionally will activate the host cellular defense mechanisms to fight SARS-CoV-2 infection.

We show that ACF is a potent, specific inhibitor of PL pro , with IC50 values in the low nanomolar range in all tested cell models. The activity is promising and by far exceeds the reported activities for GRL-0617 (Shin et al., 2020) and rac5c (Klemm et al., 2020) , both active at the micromolar range. Structural analysis revealed that the inhibitor blocks the catalytic site 20 of the PL pro . An unexpected and highly unusual mechanism of inhibition is observed, where two ACF molecules bind in the enzyme's substrate binding site. The crystal structure and validation of binding in solution using NMR confirm the mode of action of ACF. Together with the high potency in cellular models these findings identify ACF as a highly attractive repurposing molecule to inhibit SARS-CoV-2 replication.

Despite a relatively short half-life for ACF in vivo (Song et al., 2005) we have observed several orders of magnitude reduction of viral load in a humanized mice infection model. This suggests that with the development of the correct treatment regime, the therapeutic effect of ACF can be extended in humans.

Notably, in addition to SARS-CoV-2, the antiviral effect of ACF was observed for other 5 betacoronaviruses: MERS-CoV, and HCoV-OC43, but not for other genera of the Coronaviridae family (alphacoronaviruses). We believe that these data indicate broad-spectrum activity of ACF against betacoronaviruses, with the potential to target future zoonotic coronaviruses. This means ACF has therapeutic benefits not only in the current crisis but can also become an important component of the arsenal against future pandemics.

The unique and specific inhibition of SARS-CoV-2 PL pro and associated inhibition of virus replication in the cell culture, ex vivo and in vivo renders ACF an attractive compound for evaluation in the treatment of COVID-19. It has to be considered, though, that the aromatic acridine rings are linked with DNA intercalating properties and, consequently, with mutagenic potential. On the other hand, a substantial amount of long-term clinical data is available for 15 systematic applications (Gama CRB, 2020; Mathé et al., 1996; Mathé et al., 1998) , thus alleviating concerns related to the potential mutagenic effects of short-term antiviral therapy. Importantly, the antiviral effects are observed at concentrations of two to three orders of magnitude lower than those used in experiments assessing in vitro mutagenicity of ACF (Obstoy et al., 2015; Rees et al., 1989) . 20 In conclusion, we have identified a potent small-molecule inhibitor of the coronaviral PL pro that is registered and marketed as an inexpensive over-the-counter drug. The low-nanomolar IC50 and good selectivity index, combined with the profound inhibition of the viral replication in all tested models, suggest that the drug may be effective in monotherapy or in combination therapy with, e.g., polymerase inhibitors. A possible limitation for human application might be 25 that currently used therapeutic doses, which have been proven to be safe, will not lead to high enough human systemic exposures. As there are no human pharmacokinetic data available yet, systematic PK studies proving that exposures similar to these that have been effective in mice can also be achieved in humans and are well tolerated. Similarly, like other antiviral drugs, ACF may be administered early during the infection to enable the maximum effect. Specifically, an 5 elderly patient population may significantly benefit from a new antiviral treatment option, as mortality in the age group 70+ is significantly increased compared to younger groups. In addition, the antiviral effect against other betacoronaviruses argues that further research into the therapeutic potential of ACF may provide protection against future zoonotic infections of betacoronaviruses. The unique mode of inhibition of ACF will also serve as a blueprint to 10 develop new, improved drugs with a broadband activity using structure-based drug development to prepare for future coronavirus outbreaks.

Education for the research on the SARS-CoV-2 and a grant from the National Science Center UMO-2017/27/B/NZ6/02488 to KP. CoV-2 N protein is denoted in green. Each image represents maximum projection of 5 µm section. Scale bar = 20 µm. B. Antiviral activity of ACF against SARS-CoV-2 in human airway epithelium (MucilAir). The figure shows RT-qPCR analysis of HAE culture supernatants infected with SARS-CoV-2. Remdesivir and PBS were used as controls. The assay was performed at least in duplicate, and median values with range are presented. Two-way ANOVA analysis with 10 Dunnett's post-hoc test indicated that ACF and REM significantly inhibit virus yields during infection course compared to untreated control. (C.) Confocal analysis of infected HAE cultures. Cells were infected with the SARS-CoV-2 in the presence of 500 nM acriflavine, 10 µM remdesivir, or vehicle control (control). Mock images illustrate non-infected cells. On day 6 p.i. cells were fixed and immunostained. Cell nuclei are denoted in blue, actin in red and 15 SARS-CoV-2 N-protein in green. Each image represents maximum projection of 3 µm section. Scale bar = 10 µm. An asterisk indicates values that are significantly different from the non-treated control (p < 0.05). ACF: acriflavine, rem: remdesivir. (E.) Phylogenetic tree of alpha and betacoronaviruses. Three different genera of betacoronaviruses were used in the study as representants and are denoted in red. Representative viruses used in this study are denoted in red. Oral and intramuscular delivery were tested. Remdesivir was used as positive control. Virus replication in different organs was assessed using the RT-qPCR. Strong reduction of virus level is visible in the brain of treated groups. ACF caused a marked reduction of virus load in the 5 lungs when administered orally. Data are presented as geometric mean with 95% confidence intervals.

Aminoacridine Compounds as Surface Antiseptics

Proflavine and acriflavine

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Protease inhibitors targeting the main protease and papain-like protease of coronaviruses

The Drug Repurposing Hub: a next-generation drug library and information resource

Potent antimalarial activity of acriflavine in vitro and in vivo

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

acrB mutation located at carboxyl-terminal region of gyrase B subunit reduces DNA binding of DNA gyrase

Treatment of Recurrent Urinary Tract Infection Symptoms with Urinary Antiseptics Containing Methenamine and Methylene Blue: Analysis of Etiology and Treatment Outcomes

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Covid-19: Risk of death more than doubled in people who also had flu, English data show

Mechanisms of action of acriflavine: electron microscopic study 30 of cell wall changes induced in Staphylococcus aureus by acriflavine

Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2

Fields virology

A novel coronavirus associated with severe acute respiratory syndrome

Antitumor activity of 40 acriflavine in lung adenocarcinoma cell line A549

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

HAART in HIV/AIDS Treatments: Future Trends

Coinfection of SARS-CoV-2 and Other Respiratory Pathogens

Acriflavine treatment promotes dyskinetoplasty in Trypanosoma cruzi as revealed by ultrastructural analysis

The non-enumerable described retrovirus integrase inhibitors are not a lure, as evidenced by ten years of clinical experience

AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, 5 concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue

Data of preclinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics

HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV

Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis

Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment

Safety and performance analysis of acriflavine and methylene blue for in vivo imaging of precancerous lesions using fibered confocal fluorescence microscopy (FCFM): an experimental study

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

Keeping track of the SARS-CoV-2 vaccine pipeline

Activation of cGAS-dependent antiviral responses by DNA intercalating agents

RNA-sequencing analysis of Trichophyton rubrum transcriptome in response to sublethal doses of acriflavine

Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme

Optimization of metabolic activation for four mutagens in a bacterial, fungal and two mammalian cell mutagenesis assays

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Pharmacokinetics and metabolism of acriflavine in rats following intravenous or intramuscular administration of AG60, a mixture of acriflavine and 5 guanosine, a potential antitumour agent

Search of antitubercular activities in tetrahydroacridines: synthesis and biological evaluation

ISGylation -a key to lock the cell gates 10 for preventing the spread of threats

Acridine-a neglected antibacterial chromophore

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia